HealthEquity announces CTO departure and transition of technology leadership
HealthEquity, Inc. announced the termination of its Chief Technology Officer, Eli Rosner, effective April 17, with Sunil Rajasekar assuming leadership of the technology organization. Rosner will receive severance per his employment agreement, while Rajasekar, previously Executive Vice President and Chief Product and Strategy Officer, brings extensive experience from companies like Oracle, Cisco, and Billtrust. This news follows recent strong financial results for HealthEquity.
HealthEquity Announces CTO Departure and Leadership Transition
HealthEquity announced the termination of its Chief Technology Officer, Eli Rosner, effective April 17, 2026. Oversight of the technology organization will transition to Executive Vice President, Sunil Rajasekar. This move aims for a more integrated approach to technology, product, and strategy, with Rosner receiving severance and equity per his agreement.
According to the latest filing with the US Securities and Exchange Commission (SEC), health savings account service provider HealthEquity Inc. has officially appointed Sunil Rajasekar as the head of its technology department. This appointment will take effect
HealthEquity Inc. has appointed Sunil Rajasekar as the head of its technology department, effective April 17, 2026. This move, reported in a recent SEC filing, aims to strengthen technological innovation and strategic development. Rajasekar will lead the technology team, driving upgrades to technical architecture and optimizing digital solutions, which market analysts anticipate will bring greater efficiency and growth momentum.
HealthEquity announces CTO departure and transition of technology leadership
HealthEquity, Inc. announced the termination of its Chief Technology Officer, Eli Rosner, effective April 17. Sunil Rajasekar, Executive Vice President and Chief Product and Strategy Officer, will assume responsibility for the technology organization. Rosner will receive severance and benefits, and this move follows other recent news for HealthEquity, including strong Q4 financial results and an adjusted price target from RBC Capital.
HealthEquity (NASDAQ: HQY) to end CTO role as EVP Rajasekar takes over tech
HealthEquity (NASDAQ: HQY) announced the termination of its Chief Technology Officer, Eli Rosner, effective April 17, 2026, without cause. Executive Vice President and Chief Product and Strategy Officer Sunil Rajasekar will assume responsibility for the technology organization. Rosner will receive previously negotiated severance and benefits, with equity awards handled according to existing stock incentive plans.
Healthequity Inc Terminates Eli Rosner As Chief Technology Officer Effective April 17, 2026
Healthequity Inc has decided to terminate Eli Rosner from his position as Chief Technology Officer. This termination will be effective on April 17, 2026. The information was reported by Refinitiv.
A Look At HealthEquity (HQY) Valuation After Recent Mixed Short Term Share Price Moves
HealthEquity (HQY) has experienced mixed short-term share price movements, with recent gains but a decline over the past three months. Despite a potential undervaluation based on a fair value estimate of $111.63, its current P/E ratio of 33.2x is higher than industry averages, suggesting less room for error. The article encourages investors to conduct their own analysis and consider broader investment ideas.
Reasons to hold HealthEquity stock in your portfolio for now
This article suggests reasons to hold HealthEquity stock in an investment portfolio. No specific details are provided in the current content, as the article is truncated.
How HealthEquity’s (HQY) New Board Appointment Shapes Its AI-Driven Healthcare Platform Strategy
HealthEquity, Inc. recently appointed William “Bill” Gassen to its board of directors, a move that is expected to reinforce the company's focus on its AI-enabled, consumer-focused healthcare affordability platform. Gassen's expertise in rural health systems and human capital aligns with HealthEquity's strategic push into AI and digital automation for operating efficiency. While this appointment strengthens the innovation and governance narrative, the company's investment story remains sensitive to interest income, member growth, and managing operating costs in the near term.
HealthEquity (NASDAQ: HQY) notices proposed sale of 18,010 shares via Form 144
HealthEquity, Inc. (NASDAQ: HQY) has filed a Form 144, indicating a proposed sale of 18,010 shares of common stock stemming from a Restricted Stock Vesting arrangement. The filing identifies Elimelech Rosner as the reporting person and notes a previous sale of 2,074 shares on January 9, 2026, for $197,520.54. As of March 31, 2026, the company had 84,478,406 shares outstanding.
Delano Ladd sale notice — HealthEquity (NASDAQ: HQY)
This article reports a Form 144 filing by Delano Ladd concerning the proposed sale of HealthEquity (NASDAQ: HQY) common stock. The filing indicates a sale of 739 shares on January 9, 2026, for $142,080, stemming from a Restricted Stock Vesting event on March 29, 2023. The document emphasizes transparency in insider stock sales and explains key financial terms like Form 144 and restricted stock vesting for investors.
9,292-share sale planned; HealthEquity (NASDAQ: HQY) insider reported recent 791-share sale
A HealthEquity insider has filed a Form 144 indicating a planned sale of 9,292 common shares due to restricted stock vesting on March 31, 2026. The filing also disclosed a recent sale of 791 shares on January 9, 2026, by the same insider, Stephen Neeleman. These actions are routine liquidity notices related to compensation.
HealthEquity (HQY) EVP Delano Ladd shifts 7,726 shares for tax obligations
HealthEquity, Inc.'s EVP and General Counsel Delano Ladd disposed of 7,726 shares of common stock on March 31, 2026. This transaction was a tax-withholding disposition, meaning the shares, valued at $82.5264 each, were transferred to cover a tax liability rather than sold on the open market. Following this, Ladd holds 0 shares in this specific reported holding line, as detailed in a Form 4 SEC filing.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HealthEquity (HQY) stock is recommended as a hold due to its strong business model, impressive fourth-quarter fiscal 2026 performance, and growth in Health Savings Accounts (HSAs). The company is leveraging AI for efficiency and saw a significant increase in HSA assets and accounts. Despite potential data security threats, HealthEquity's financial improvements and continued growth in the HSA market contribute to its positive outlook.
HealthEquity (NASDAQ: HQY) CTO has 18,010 shares withheld for taxes
HealthEquity's EVP and Chief Technology Officer, Elimelech Rosner, had 18,010 shares of common stock withheld for tax obligations at an average price of $82.5264 per share. This transaction, a non-market tax-withholding disposition, is a routine event for executives covering taxes on equity compensation. Following this, Rosner directly holds 86,265 shares of HealthEquity common stock.
HealthEquity (NASDAQ: HQY) founder covers tax bill with shares
HealthEquity founder and vice chairman Stephen Neeleman reported a tax-withholding disposition of 9,292 shares of common stock at $82.5264 per share on March 31, 2026. These shares were withheld to satisfy tax obligations, not sold in an open-market transaction. After this event, he directly holds 141,227 common shares, with additional shares held indirectly through trusts and family entities.
Reasons to Consider Keeping HealthEquity Shares in Your Portfolio at This Time
HealthEquity (HQY) shows strong performance fueled by AI integration and significant growth in Health Savings Accounts (HSAs), with total assets reaching $36.5 billion. Despite strong Q4 fiscal 2026 results and positive earnings revisions for fiscal 2027, the company faces ongoing data security risks which necessitate continuous investment in prevention measures. HealthEquity has consistently beaten earnings estimates, making it a compelling consideration for investors despite its "Hold" rating from Zacks.
Reasons to Consider Keeping HealthEquity Shares in Your Portfolio at This Time
HealthEquity, Inc. (HQY) shares are recommended for retention due to strong Q4 fiscal 2026 performance, significant growth in Health Savings Accounts (HSAs), and operational efficiencies driven by AI. While data security remains a concern, the company has consistently exceeded earnings estimates and analysts anticipate continued growth in fiscal 2027. The article also suggests alternative investment opportunities in the medical sector.
Allspring Global Investments Holdings LLC Sells 34,677 Shares of HealthEquity, Inc. $HQY
Allspring Global Investments Holdings LLC reduced its stake in HealthEquity, Inc. by 4.5% in the fourth quarter, selling 34,677 shares, though it still holds approximately 0.85% of the company valued at $66.44 million. Despite this reduction, Wall Street analysts maintain a "Moderate Buy" rating for HealthEquity, with a consensus target price of $110.36, and the company recently surpassed earnings and revenue estimates. HealthEquity specializes in consumer-directed health accounts and benefits, with institutional investors owning 99.55% of its stock.
HealthEquity Adds Sanford Health CEO Bill Gassen to Board
HealthEquity announced the appointment of William "Bill" Gassen, President and CEO of Sanford Health, to its board of directors, expanding it to ten members. Gassen will serve on the Audit and Risk Committee and the Talent, Compensation and Culture Committee, bringing expertise in healthcare delivery and financing. Analysts currently rate HQY stock as a Buy with a $110.00 price target, and TipRanks’ AI Analyst, Spark, also rates it as an Outperform due to strong financial performance and raised guidance, despite weaker technical momentum.
HealthEquity, Inc. (NASDAQ:HQY) Given Consensus Recommendation of "Moderate Buy" by Brokerages
HealthEquity, Inc. (NASDAQ:HQY) has received a consensus "Moderate Buy" rating from fifteen brokerages, with an average 1-year target price of $110.36. The company recently surpassed earnings expectations, reporting an EPS of $0.95 against a $0.90 consensus and revenue of $334.6 million, an increase of 7.3% year-over-year. Major institutional investors have significantly increased their stakes in HealthEquity, contributing to its nearly 99.55% institutional ownership.
HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors
HealthEquity, Inc. (NASDAQ: HQY) has appointed William ‘Bill’ Gassen, president and CEO of Sanford Health, to its board of directors, effective March 26, 2026. Gassen's extensive experience in leading a complex health system is expected to provide valuable insight into healthcare delivery and financing for HealthEquity. He will also serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee, expanding the Board to 10 directors.
HealthEquity Adds Sanford Health CEO Bill Gassen to Board
HealthEquity (HQY) has appointed William "Bill" Gassen, President and CEO of Sanford Health, to its board of directors, expanding the board to ten members. This appointment, effective March 26, 2026, is expected to enhance HealthEquity's understanding of healthcare delivery and financing, leveraging Gassen's experience with the nation's largest rural health system. The move also reflects growing commercial ties between the two entities, with Sanford Health generating significant revenue for HealthEquity.
Sanford Health CEO joins HealthEquity (NASDAQ: HQY) board, expanding it to 10
HealthEquity, Inc. (NASDAQ: HQY) has appointed William "Bill" Gassen, President and CEO of Sanford Health, to its board of directors, effective March 26, 2026. This appointment increases the board size to ten directors, with eight being independent, and Gassen will serve on the Audit and Risk Committee and the Talent, Compensation and Culture Committee. HealthEquity also has an ongoing business relationship with Sanford Health, from which it generated over $123,000 in revenue for consumer-directed benefits in the last fiscal year.
HealthEquity (HQY) director William Gassen discloses 734 shares, RSUs vesting June 2026
HealthEquity director William Gassen has filed an initial ownership report, disclosing a direct holding of 734 common shares in the company. These shares are in the form of Restricted Stock Units (RSUs) which are set to vest fully in June 2026, coinciding with the company's annual stockholder meeting. This move establishes his equity stake and aligns his compensation with HealthEquity's future performance.
Sanford Health CEO joins HealthEquity board, expands it to 10
HealthEquity (NASDAQ: HQY) has appointed William "Bill" Gassen, President and CEO of Sanford Health, to its board of directors, effective March 26, 2026. This appointment expands the board to 10 directors, with Gassen joining the Audit and Risk Committee and the Talent, Compensation and Culture Committee. Gassen brings significant experience from leading the nation's largest rural health system and serving on the Oscar Health board, enhancing HealthEquity's perspective on healthcare delivery and financing.
HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors
HealthEquity, Inc. announced the appointment of William 'Bill' Gassen, President and CEO of Sanford Health, to its board of directors, effective March 26, 2026. Gassen will also serve on the Audit and Risk Committee and the Talent, Compensation and Culture Committee, expanding the board to 10 directors. This appointment is expected to strengthen HealthEquity's perspective on healthcare system challenges given Gassen's extensive experience in leading a large, complex health system.
Avoiding Lag: Real-Time Signals in (HQY) Movement
This article from Stock Traders Daily provides a real-time analysis of Healthequity Inc. (HQY) stock, highlighting a strong near and mid-term sentiment but a weak long-term outlook. It details specific trading strategies, including long, momentum breakout, and short risk hedging options, based on AI-generated signals and multi-timeframe analysis. The report also points out an exceptional 40.5:1 risk-reward short setup.
HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors
HealthEquity, Inc. (NASDAQ: HQY) has appointed William ‘Bill’ Gassen, president and CEO of Sanford Health, to its board of directors, effective March 26, 2026. Gassen's extensive experience leading a large health system is expected to provide valuable insight into healthcare delivery, financing, and consumer friction, strengthening HealthEquity's mission to help people save and pay for healthcare. He will also serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee, expanding the Board to 10 directors.
HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors
HealthEquity, Inc. (NASDAQ: HQY) has appointed William ‘Bill’ Gassen, president and CEO of Sanford Health, to its board of directors, effective March 26, 2026. Gassen's extensive experience in healthcare delivery and finance is expected to strengthen HealthEquity's mission to help consumers save for and manage healthcare costs. He will also serve on the Audit and Risk Committee and the Talent, Compensation and Culture Committee.
HealthEquity (NASDAQ:HQY) Rating Lowered to "Hold" at Wall Street Zen
Wall Street Zen has downgraded HealthEquity (NASDAQ:HQY) from a "buy" to a "hold" rating. Despite this, HealthEquity recently surpassed analyst earnings and revenue estimates. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $110.36, while trading near $82.51.
HealthEquity (HQY) founder reports new stock grants and options
HealthEquity (HQY) founder and Vice Chairman Stephen Neeleman reported new equity compensation awards, including 15,915 restricted stock units with vesting starting in April 2027, and 23,860 common shares from previously vested restricted stock units. These transactions increase his direct common stock holdings to 150,519 shares. Neeleman also retains various stock options with exercise prices between $41.28 and $73.61, expiring from 2027 to 2029.
HealthEquity (NASDAQ: HQY) EVP and General Counsel granted RSUs and shares
HealthEquity (NASDAQ: HQY) Executive Vice President and General Counsel Delano Ladd received 15,157 restricted stock units (RSUs) as a new grant and had an additional 20,451 RSUs vest and convert into shares. Following these transactions, Ladd directly holds 108,848 shares of the company's common stock. The newly granted RSUs will vest over time, with 25% vesting on April 1, 2027, and quarterly thereafter.
HEALTHEQUITY (HQY) grants 15,157 RSUs to Chief Customer Officer
HealthEquity's Chief Customer Officer, Michael Gathright, was granted 15,157 restricted stock units (RSUs) as an equity award. These RSUs will vest over time, with 25% vesting on April 1, 2027, and subsequent quarterly vesting periods. Following this grant, Gathright directly holds 42,163 shares of HealthEquity common stock.
HealthEquity (HQY) EVP granted 17,582 restricted stock units, now holds 65,633 shares
Michael Henry Fiore, EVP and Chief Commercial Officer at HealthEquity (HQY), received a grant of 17,582 restricted stock units (RSUs), increasing his direct holdings to 65,633 shares. These RSUs will vest 25% on April 1, 2027, followed by 6.25% quarterly for the subsequent twelve quarters. This transaction is classified as an equity compensation award rather than an open-market purchase or sale.
HEALTHEQUITY (HQY) CTO adds shares through RSU grant and vesting
HEALTHEQUITY's EVP and CTO, Elimelech Rosner, reported new stock-based compensation activity. He received a grant of 19,704 Restricted Stock Units (RSUs) with a staggered vesting schedule and also saw 40,903 RSUs vest into common stock on March 25, 2026. Following these transactions, Rosner now directly holds 104,275 shares of HEALTHEQUITY common stock.
HealthEquity (NASDAQ: HQY) CFO granted 27,283 stock units
HealthEquity's EVP & CFO, James M. Lucania, was granted 27,283 restricted stock units (RSUs) as compensation, bringing his total direct holdings to 111,849 shares. These RSUs vest 25% on April 1, 2027, with the remaining shares vesting quarterly over the subsequent twelve quarters. This transaction was not an open-market purchase but an equity award recorded at a $0.00 purchase price.
HealthEquity (HQY) CEO receives 72,754 restricted stock units award
HealthEquity, Inc. CEO Scott Cutler was awarded 72,754 restricted stock units as compensation, not through an open-market purchase. These units, which represent a contingent right to one share of common stock each, will vest in a staggered schedule, starting with 25% on April 1, 2027, and subsequently 6.25% each quarter for the following twelve quarters. Following this grant, Cutler directly owns a total of 182,574 shares of HealthEquity common stock.
Should HealthEquity’s Upgraded Outlook and Buyback Completion Require Action From HealthEquity (HQY) Investors?
HealthEquity (HQY) reported strong Q4 and full-year results, including a US$122.34 million share repurchase program. The company also raised its earnings outlook for fiscal year 2027, projecting higher revenue, net income, and diluted EPS. However, investors are cautioned to consider the risk of declining interest rates on the company's interest income from custodial cash, despite the positive guidance.
Should HealthEquity’s Upgraded Outlook and Buyback Completion Require Action From HealthEquity (HQY) Investors?
HealthEquity, Inc. recently reported increased fourth-quarter and full-year revenues and net income, along with the completion of a US$122.34 million share repurchase program. The company also raised its earnings outlook for fiscal year 2027, projecting higher revenue and net income. While this signals management confidence and reinforces near-term earnings catalysts, investors should remain mindful of risks such as dependence on interest income from custodial cash and varying fair value estimates from analysts.
Congress Asset Management Co. Buys 27,102 Shares of HealthEquity, Inc. $HQY
Congress Asset Management Co. has increased its stake in HealthEquity, Inc. (NASDAQ:HQY) by 36.3%, acquiring an additional 27,102 shares. This brings their total holdings to 101,816 shares, valued at approximately $9.33 million. HealthEquity has seen significant institutional investment, with Norges Bank and AQR Capital Management LLC also making substantial moves, and institutional investors now owning 99.55% of the company's stock.
HealthEquity Inc stock faces pressure amid insider sales and GLP-1 platform launch on NASDAQ
HealthEquity Inc. (NASDAQ: HQY) is experiencing pressure on its stock due to recent insider sales, despite launching new GLP-1 telehealth and HSA enrollment platforms. While these innovations target the growing weight-loss medication market and streamline health savings account management, investor caution is warranted given the mixed Signals of product innovation and executive share divestments. The company's market leadership in HSA administration and favorable analyst ratings suggest growth potential, but upcoming quarterly results and the sustained impact of new platforms on revenue will be critical.
One company’s million-dollar gambit to turn the healthcare crisis into a gold mine
HealthEquity, the largest administrator of Health Savings Accounts (HSAs), is experiencing record sales and earnings, attributing its success to Trump administration policy changes that expanded HSA eligibility. The company recently donated $1 million to President Trump’s Super PAC, MAGA, Inc., and is now advocating for further dramatic expansions of the HSA market. Critics argue that HSAs primarily benefit wealthy Americans as tax shelters and retirement funds, while doing little to improve healthcare affordability or quality for working-class individuals, often tied to high-deductible plans that cause people to skip necessary care.
HealthEquity Inc stock faces scrutiny amid slowing HSA growth and rising competition in US benefits
HealthEquity Inc. (HQY) reported softer Q1 fiscal 2026 results with a 5% revenue increase, but membership additions fell short of expectations, causing an 8% stock drop. The company faces challenges from slowing Health Savings Account (HSA) adoption, increased competition, and interest rate pressures, although its dominant market position and strategic pivots offer long-term potential. Investors are watching for regulatory changes and the impact of tech investments on margins.
HealthEquity, Inc. (NASDAQ:HQY) Q4 2026 Earnings Call Transcript
HealthEquity, Inc. (HQY) reported strong Q4 and full-year fiscal 2026 results, exceeding earnings expectations with significant EBITDA growth, margin expansion, and record HSA sales. The company highlighted advancements in its "save, spend, invest" flywheel strategy, especially in mobile engagement and AI integration for enhanced member experience and operational efficiency. HealthEquity also provided raised guidance for fiscal 2027, anticipating continued revenue growth and margin expansion, supported by favorable policy changes expanding HSA eligibility through ACA exchanges.
HealthEquity Analysts Cut Their Forecasts After Q4 Results
HealthEquity Inc. reported better-than-expected Q4 earnings and sales, with adjusted EPS of 95 cents and sales of $334.586 million. The company raised its FY2027 sales guidance due to record new HSAs and significant margin expansion, leading to a 23% increase in Adjusted EBITDA. Despite the strong performance, several analysts from RBC Capital, JP Morgan, and Barrington Research lowered their price targets for HealthEquity shares.
BMO Maintains Market Perform on HealthEquity (HQY) March 18, 2026
BMO Capital has maintained a Market Perform rating on HealthEquity, Inc. (HQY) as of March 18, 2026, indicating steady expectations rather than bullish conviction. While the firm raised its FY27 outlook, no new price target was issued, leading to a muted market reaction. Investors are advised to view this as neutral guidance, suggesting holding the stock while monitoring future performance.
HealthEquity Inc. Earnings Call Highlights Profitable Growth
HealthEquity Inc. (HQY) reported strong Q4 earnings, demonstrating profitable growth driven by record HSA sales, margin expansion, and robust cash generation. The company added over a million new HSAs during the fiscal year, bringing total accounts to 17.8 million, and total HSA assets surpassed $36 billion. HealthEquity raised its fiscal 2027 revenue guidance, reflecting confidence in sustained growth, though challenges like slower service revenue and the early stage of its marketplace initiative were noted.
Crown Advisors Management Inc. Invests $1.90 Million in HealthEquity, Inc. $HQY
Crown Advisors Management Inc. has acquired a new stake in HealthEquity, Inc. (NASDAQ:HQY) during the third quarter, purchasing 20,000 shares valued at approximately $1.90 million. This investment represents about 1.3% of Crown Advisors' portfolio, making HealthEquity its 29th largest holding. HealthEquity recently reported strong Q4 results, beating estimates and raising fiscal 2027 guidance, with record revenue of $1.31 billion and net income up 123%.
HealthEquity Analysts Cut Their Forecasts After Q4 Results
HealthEquity (NASDAQ: HQY) reported better-than-expected Q4 earnings and raised its FY2027 sales guidance. Despite this, the company's shares slipped, and several analysts, including those from RBC Capital, JP Morgan, and Barrington Research, maintained their ratings but lowered their price targets for the stock. This comes as the company continues to see strong growth in HSA accounts and assets.
